Bambusa Therapeutics Prices Upsized Nasdaq IPO
Bambusa Therapeutics, a Vietnam-based oncology biotech, priced its Nasdaq IPO on November 2, 2026, increasing the offering size. The company employs an offshore holding structure with R&D collaborations in Vietnam and Singapore, and holds no direct PRC operating entities. Its pipeline focuses on targeted cancer therapies.
51CFO view：CFOs of APAC-focused biotechs must model revenue under FDA/EMA dual-path scenarios, apply ASC 730 to global clinical trial costs, and ensure executive bios avoid references to PRC-affiliated roles. Teams need IFRS/US GAAP translation fluency and Southeast Asia tax coordination capability — not just US-listing readiness.
Bambusa Therapeutics, a Vietnam-based oncology biotech, priced its Nasdaq IPO on November 2, 2026, increasing the offering size. The company employs an offshore holding structure with R&D collaborations in Vietnam and Singapore, and holds no direct PRC operating entities. Its pipeline focuses on targeted cancer therapies.
Source：Google News · 美股 IPO
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →
What to do 18 months before filing
Financial readiness: audit basis, internal control, equity restatement.
Read →